Zymeworks Authorizes 2026 Share Repurchase Program, Affirms Liquidity
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) just unveiled an announcement.
On May 14, 2026, Zymeworks Inc. announced that its board had authorized a new 2026 share repurchase program allowing the company to buy back up to $125 million of its common stock, while terminating the prior 2025 authorization after repurchasing about 4.2 million shares for $102.3 million at an average price of $24.36. As of May 13, 2026, the biotech reported roughly 73 million shares outstanding and said the new program, to be funded from its balance sheet and executed in accordance with securities rules, is intended to return capital efficiently to shareholders while preserving flexibility to invest in its R&D pipeline and strategic opportunities.
The company also stated that, based on current operating plans and assuming full use of the $125 million 2026 repurchase program, it currently expects its existing cash as of March 31, 2026, together with $440 million in anticipated regulatory milestone payments tied to potential approvals of Ziihera for gastric and esophageal adenocarcinoma in the U.S., Europe, Japan, and China, to fund operations beyond 2028. This projected cash runway excludes any upside from future milestones, royalties on Ziihera or other licensed programs, or new partnerships, underscoring management’s confidence in its liquidity position but also highlighting that outcomes remain sensitive to regulatory, commercial, and collaboration-related risks.
The most recent analyst rating on (ZYME) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and heavy cash burn) and limited valuation support (negative P/E). It is partially offset by constructive earnings-call fundamentals (near-term regulatory catalysts, potential milestones, improved cash position) and supportive liquidity-related corporate actions, while technicals remain mixed with near-term weakness.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global biotechnology company that manages a portfolio of licensed healthcare assets while developing a pipeline of novel, multifunctional biotherapeutics for difficult-to-treat diseases, including cancer, inflammation, and autoimmune conditions. Its asset and royalty aggregation strategy centers on licensed products such as Ziihera (zanidatamab-hrii) and other candidates like pasritamig, supported by proprietary antibody platforms and collaborations with major biopharmaceutical partners.
The company engineered and developed Ziihera, a HER2-targeted bispecific antibody built on its Azymetric technology, and has granted exclusive development and commercialization rights for zanidatamab in different territories to BeOne Medicines and Jazz Pharmaceuticals. Zymeworks aims to build a portfolio of cash-generating healthcare assets alongside its internal R&D engine in antibody drug conjugates and multispecific antibody therapeutics, leveraging these capabilities to create differentiated antibody-based medicines and long-term value for stakeholders.
Average Trading Volume: 663,181
Technical Sentiment Signal: Buy
Current Market Cap: $1.76B
Learn more about ZYME stock on TipRanks’ Stock Analysis page.
